In T2DM, optimal transition from monotherapy to combination therapy is essential to maintain glycemic control and minimize disease progression. Early combination therapy is recommended by current clinical guidelines in order to address both insulin resistance and deficiency in insulin secretion.[4,5] Combination therapy offers a number of advantages related to decreased incidence of adverse events, improved compliance and economic benefits. In addition, FDC medications have demonstrated improved compliance.
Repaglinide and metformin target two different pathophysiological mechanisms underlying T2DM. Combination therapy with repaglinide plus metformin in the form of a single tablet has proven in several clinical studies to be a safe and effective therapeutic option for patients with T2DM with inadequate glycemic control. In addition, single-tablet combination therapy offers enhanced convenience in terms of dosing and patient adherence.
Financial & competing interests disclosure
Robert G Moses received honoraria from NovoNordisk for ad hoc expert committees, income related to clinical trials and also sponsorship to some international meetings. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Robert G Moses wishes to thank Anu Santhanagopal of DesignWrite, LLC, for providing medical writing and editorial assistance. Funding to support the preparation of this manuscript was provided by Novo Nordisk A/S.
Expert Rev Endocrinol Metab. 2010;5(3):331-342. © 2010 Expert Reviews Ltd.
Cite this: Combination Therapy for Patients with Type 2 Diabetes: Repaglinide in Combination with Metformin - Medscape - May 01, 2010.